+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Immune Response to Two Different Hepatitis B Vaccines in Haemodialysis Patients: A 2-Year Follow-Up

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Formalin-inactivated hepatitis B vaccine was given at 0,1 and 6 months to 22 medical staff members and to 37 haemodialysis patients. After vaccination with 20 μg surface antigen (HBsAg), seroconversion occurred in 95% of the staff members. Following immunisation with a double dose, only 74% of the haemodialysis patients developed antibodies against HBsAg (anti-HBs). Anti-HBs levels were lower in the patient group and 6 responders (23%) became anti-HBs-negative within 2 years. 40 other haemodialysis patients were immunised at monthly intervals with either three doses of 3 μg or three doses of 27 μg heat-inactivated hepatitis B vaccine. Seroconversion was achieved in 60% of the patients in the 3-μg group and in 95% of the patients in the 27-μg group. Anti-HBs levels increased significantly when the high dose was used. Although the study design does not allow a definite conclusion, it appears that the immunogenicity per microgramme HBsAg is higher for the heat-inactivated vaccine than for the formalin-inactivated vaccine. The findings further indicate that decreased immune response to hepatitis B vaccination in haemodialysis patients can be improved by increasing the dose of the vaccine. A booster injection should be considered in these patients within 2 years after the first vaccination.

          Related collections

          Author and article information

          S. Karger AG
          24 December 2008
          : 40
          : 2
          : 155-160
          Department of aNephrology, bEpidemiology and Ηepatology, University Hospital, Groningen, The Netherlands
          183453 Nephron 1985;40:155–160
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper

          Cardiovascular Medicine, Nephrology

          Haemodialysis, Hepatitis B, Immune response, Vaccination


          Comment on this article